Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349969 | 0.82 | ENPP2 (0.42) | ENPP2ATXN2TRPV1FLT3HTR2A | |
| SCHEMBL351272 | 0.80 | ENPP2 (0.43) | ENPP2ATXN2TRPV1FLT3HTR2A | |
| SCHEMBL351914 | 0.80 | ENPP2 (0.47) | ENPP2ATXN2FLT3PTGDR2 | |
| SCHEMBL351484 | 0.79 | ENPP2 (0.37) | ENPP2ATXN2FLT3PTGDR2 | |
| SCHEMBL351111 | 0.77 | PTGDR2 (0.39) | ENPP2ATXN2TRPV1PTGDR2 | |
| SCHEMBL145635 | 0.77 | HDAC1 (0.50) | ENPP2ATXN2TRPV1HIF1AEPAS1 | |
| SCHEMBL2810678 | 0.76 | ENPP2 (0.40) | ENPP2ATXN2TRPV1FLT3HIF1A | |
| SCHEMBL351757 | 0.75 | PDE5A (0.38) | ENPP2ATXN2TRPV1PTGDR2 | |
| SCHEMBL350135 | 0.75 | ENPP2 (0.41) | ENPP2ATXN2FLT3PTGDR2 | |
| SCHEMBL143425 | 0.74 | SMN1; SMN2 (0.53) | ENPP2ATXN2TRPV1HTR2AABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | claimed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | claimed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | claimed |
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | ENPP2 1/4885ATXN2 601/4885TRPV1 3023/4885 |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | ENPP2 1/4885ATXN2 601/4885TRPV1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.